CP# 02.01.01 Maternal genetic testing CP# 02.01.02 Genetic testing for breast and ovarian cancer CP# 02.01.03 Array comparative genomic hybridization testing CP# 02.01.13 Pharmacogenetic testing for warfarin CP# 02.01.07 Genetic testing for cystic fibrosis CP# 02.01.08 Familial polyposis gene testing CP# 02.01.10 COLARIS® test for Lynch syndrome CP# 02.01.11 AfirmaTM gene expression classifier ...

Introduction Over the past decade, the oncology community has witnessed a revolution in our understanding of the biology of lung cancer with the identification of a significant proportion of patients whose tumors harbor targetable molecular changes. these recurrent genomic alterations include mutations, gene rearrangements, and copy number changes in relevant lung cancer genes (Figure 1). A var...

Recent genomic sequencing studies have provided valuable insight into genetic aberrations in head and neck squamous cell carcinoma. Despite these great advances, certain hurdles exist in translating genomic findings to clinical care. Further correlation of genetic findings to clinical outcomes, additional analyses of subgroups of head and neck cancers and follow-up investigation into genetic he...

Molecular-focused cancer therapies, e.g., molecularly targeted therapy and immunotherapy, so far demonstrate only limited efficacy in cancer patients. We hypothesize that underestimating the role of biophysical factors that impact the delivery of drugs or cytotoxic cells to the target sites (for associated preferential cytotoxicity or cell signaling modulation) may be responsible for the poor c...

The treatment of acute myeloid leukaemia (AML) remains challenging, given the disease's heterogeneous genomics, epigenetics and immunology. Although novel drugs are rapidly being developed, outcomes patients with AML remain suboptimal, especially among individuals older than 75 years those primary relapsed/refractory disease. While molecular characterization can inform use targeted therapies, s...

In the last half of the century, advances in the systemic therapy of cancer, including chemotherapy, hormonal therapy, targeted therapy, and immunotherapy have been responsible for improvements in cancer related mortality in developed countries even as the population continues to age. Although such advancements have yet to benefit all cancer types, systemic therapies have led to an improvement ...

We aim to uncover robust subtypes having distinct biological characteristics associated with clinical outcome and identify subtype-specific therapeutic targets. Genomic data from 2527 gastric tumors are used clinically relevant molecular subtypes. Cluster of clusters assignment (COCA) approach was applied integrate 8 genomic consensus For validation, we identified 120 genes whose expression is ...